News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Moneyweb Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Lexaria Bioscience Corp. has announced a Material Transfer Agreement (MTA) with PegBio Co., Ltd to explore Lexaria's DehydraTECH technology with a proprietary PegBio GLP-1 molecule for the GLP-1 industry. This collaboration aims to evaluate the pharmacokinetic performance of the combined technology in animal studies, …
Lexaria Bioscience (LEXX) received a delisting notice from Nasdaq on August 4, 2026, due to non-compliance with the $1.00 minimum bid price rule. The company has requested a hearing, which temporarily stays the delisting. Following an August 3 reverse stock split, LEXX's stock price …
Lexaria Bioscience Corp (LEXX) has an earnings forecast score of 8.00, ranking 56th in the Pharmaceuticals industry. Analysts have set an average price target of $6.00 for LEXX, with a majority recommending a "Buy" trend. The company's expected revenue for the next quarter is …
This article provides a brief update on Lexaria Bioscience Corp (LEXX) stock news, indicating that more news is expected soon. It includes current stock performance metrics such as the share price, market cap, and a note that quotes are delayed by 15 minutes. The …
Lexaria Bioscience Corp. is providing an update on its human nicotine study NIC-H22-1, which will compare its DehydraTECH-nicotine pouch performance to leading brands like ON! and Zyn. The study aims to demonstrate improved oral-tissue absorption and reduced negative experiences with DehydraTECH-nicotine. Lexaria expects to …
Lexaria Bioscience Corp. (Nasdaq: LEXX) has announced a 1-for-15 reverse stock split, effective August 3, 2026, to increase its share price and regain compliance with Nasdaq's minimum $1.00 bid price rule. This strategic move aims to stabilize uncertain stock conditions and enhance the company's …
Lexaria Bioscience Corp. (NASDAQ:LEXX) announced a 1-for-15 reverse stock split to become effective on August 3, 2026. This action aims to reduce the number of issued shares and regain compliance with NASDAQ's minimum $1.00 bid price requirement. The company anticipates appealing any delisting notification …
Lexaria Bioscience will implement a 1-for-15 reverse stock split effective August 3, 2026, to meet Nasdaq's minimum bid price requirement and maintain its listing. This action will consolidate issued shares from 24,787,446 to 1,652,518 and reduce authorized shares, with fractional shares rounded up and …
Lexaria Bioscience (Nasdaq: LEXX) will execute a 1-for-15 reverse stock split on August 3, 2026, to meet Nasdaq's $1.00 minimum bid price requirement. This split will reduce outstanding shares from 24.79 million to about 1.65 million, while authorized shares will decrease from 220 million …
Lexaria Bioscience Corp (LEXX.O) has announced a 1-for-15 reverse stock split, as detailed in an SEC filing. The reverse stock split is scheduled to become effective on August 3, 2026. This corporate action aims to consolidate the company's shares.
This article provides a revenue breakdown for Lexaria Bioscience Corp. (NASDAQ: LEXX), detailing its financial performance in the last fiscal year. The company generated $700,000 USD, with the majority ($696,000 USD) coming from Intellectual Property Licensing. The United States and Canada were the largest …
This article provides historical dividend and stock split information for Lexaria Bioscience Corp (LEXX). It reports that the company has distributed a total of $0.00 in dividends over the past 5 years. The page includes current stock price, market cap, and links to other …
This article details the shareholder structure of Lexaria Bioscience Corp (LEXX), identifying its major individual and institutional investors. It provides a breakdown of shareholding by type and offers a historical view of institutional holdings and changes in ownership by key shareholders over time.
This article provides a detailed cash flow statement for Lexaria Bioscience Corp (LEXX), presenting annual and quarterly data for operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and how Lexaria Bioscience Corp performed in these …
This article provides a detailed financial overview of Lexaria Bioscience Corp (LEXX), including its current stock price, market capitalization, and key financial metrics. It presents in-depth income statement, balance sheet, and cash flow statement data, along with year-on-year changes for various financial indicators up …
Lexaria Bioscience Corp. (LEXX) is a Canada-based biotechnology company focusing on its patented DehydraTECH drug delivery platform. This technology aims to improve oral drug absorption and reduce side effects, particularly for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) therapies. The company holds a …
Lexaria Bioscience Corp (LEXX) currently holds a valuation score of 6.27, placing it 148th out of 155 companies in the Pharmaceuticals industry. The article highlights that the company's P/E ratio is -1.20, significantly below its recent high but above its recent low. Additionally, key …
This article provides a technical analysis of Lexaria Bioscience Corp (LEXX), detailing its current price momentum score, support and resistance levels, and indicator and moving average readings. It notes that LEXX has a price momentum score of 4.38 and is trading between a resistance …
This article focuses on the "Price to book forward" metric for Lexaria Bioscience Corp. (NASDAQ: LEXX). The content appears to be a stub or a section of a financial data page rather than a full analytical article, primarily displaying navigational and informational links related …
Search by ticker symbol or company name and select a result to open its chart.